tiprankstipranks
Gossamer Bio downgraded to Market Perform from Outperform at Raymond James
The Fly

Gossamer Bio downgraded to Market Perform from Outperform at Raymond James

Raymond James analyst Timur Ivannikov downgraded Gossamer Bio (GOSS) to Market Perform from Outperform without a price target following the publication of Merck’s (MRK) sotatercept’s Phase 3 data. The analyst already thought seralutinib would exhibit weaker efficacy than sotatercept in comparable populations, but says "the story got even worse" with sotatercept’s Phase 3 STELLAR outperforming Phase 2 PULSAR. Merck reported a difference of 40.8m in Phase 3 compared to LSMD of 24.9m in Phase 2, which makes the development path for Gossamer’s seralutinib even more difficult, the analyst tells investors in a research note.

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on GOSS:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles